May 27, 2010
XANODYNE ANNOUNCES PLANNED PRESIDENT & CEO SUCCESSION
May 7, 2010
XANODYNE ANNOUNCES RENEWED FOCUS ON PAIN MANAGEMENT MARKET
April 1, 2010
XANODYNE AND FERRING ANNOUNCE CO-PROMOTE FOR ZIPSOR
[ Corporate Governance ]
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. We market a portfolio of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in pain management.
Recently Approved: Zipsor® for the treatment of mild to moderate acute pain in adults was approved by the FDA on June 16, 2009.
We are Developing: XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. XP21B for the treatment of acute pain is in Phase 2 development.
Zipsor® is the first liquid filled capsule NSAID with ProSorb® technology indicated for mild to moderate acute pain in adults (18 years or older)... [MORE]
Oramorph is a sustained release morphine tablet indicated for pain in patients who require opioid analgesia for more than a few days... [MORE]
DuetDHA with Ferrazone® and enteric-coated omega-3 fatty acids is a prescription prenatal vitamin that provides the right amounts of key vitamins and minerals designed to be well tolerated.... [MORE]
